Dataset Information

Coenzyme Q10 supplementation for prophylaxis in adult patients with migraine-a meta-analysis.

ABSTRACT:

Objective

To determine the effects of coenzyme Q10 (CoQ10) for reduction in the severity, frequency of migraine attacks and duration of headache in adult patients with migraine.

Design

Systematic review and meta-analysis.

Data sources

Cochrane Central Register of Controlled Trials, CENTRAL, MEDLINE, EMBASE, Cumulative Index to Nursing and Allied Health Literature (CINAHL) and Psychological Information Database (PsycINFO) from inception till December 2019.

Study selection

All randomised control trials comparing CoQ10 with placebo or used as an adjunct treatment included in this meta-analysis. Cross-over designs and controlled clinical trials were excluded.

Data synthesis

Heterogeneity at face value by comparing populations, settings, interventions and outcomes were measured and statistical heterogeneity was assessed by means of the I² statistic. The treatment effect for dichotomous outcomes were using risk ratios and risk difference, and for continuous outcomes, mean differences (MDs) or standardised mean difference; both with 95% CIs were used. Subgroup analyses were carried out for dosage of CoQ10 and if CoQ10 combined with another supplementation. Sensitivity analysis was used to investigate the impact risk of bias for sequence generation and allocation concealment of included studies.

Results

Six studies with a total of 371 participants were included in the meta-analysis. There is no statistically significant reduction in severity of migraine headache with CoQ10 supplementation. CoQ10 supplementation reduced the duration of headache attacks compared with the control group (MD: -0.19; 95%?CI: -0.27 to -0.11; random effects; I² statistic=0%; p<0.00001). CoQ10 usage reduced the frequency of migraine headache compared with the control group (MD: -1.52; 95%?CI: -2.40 to -0.65; random effects; I² statistic=0%; p<0.001).

Conclusion

CoQ10 appears to have beneficial effects in reducing duration and frequency of migraine attack.

Prospero registration number

CRD42019126127.

SUBMITTER: Sazali S

PROVIDER: S-EPMC7786797 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Coenzyme Q10 supplementation for prophylaxis in adult patients with migraine-a meta-analysis.

Sazali Suhairul S Badrin Salziyan S Norhayati Mohd Noor MN Idris Nur Suhaila NS

BMJ open 20210105 1

<h4>Objective</h4>To determine the effects of coenzyme Q10 (CoQ10) for reduction in the severity, frequency of migraine attacks and duration of headache in adult patients with migraine.<h4>Design</h4>Systematic review and meta-analysis.<h4>Data sources</h4>Cochrane Central Register of Controlled Trials, CENTRAL, MEDLINE, EMBASE, Cumulative Index to Nursing and Allied Health Literature (CINAHL) and Psychological Information Database (PsycINFO) from inception till December 2019.<h4>Study selection ...[more]

PMID: 33402403

Similar Datasets

Project description:Feverfew (Tanacetum parthenium L.), magnesium and coenzyme Q10 are frequently used for migraine prophylaxis. Supplementation with a fixed combination of these three agents (Antemig®, PiLeJe) was investigated in an observational study.Adult patients suffering from migraine according to the criteria of the International Headache Society were enrolled by general practitioners (?2 migraine attacks during previous month; exclusion of chronic migraine and medication overuse) and after a one-month baseline phase, supplemented with one tablet of 100 mg feverfew, 100 mg coenzyme Q10 and 112.5 mg magnesium per day for 3 months.Supplementation significantly reduced the number of days with migraine headache during third month of supplementation compared to baseline phase (1.3 days ±1.5 versus 4.9 days ±2.6, p < 0.0001; n = 68 intention to treat; primary criterion). The decrease was progressive over the period of supplementation and significant from first month (1st month: -2.5 days ±3.1, p < 0.0001; 2nd month: -3 days ±2.8, p < 0.0001). The proportion of patients with a reduction of at least 50% in the number of days with migraine headache was 75% (51/68) after 3 months, with a progressive increase over the period of supplementation (63.2% [43/68] after 1 month and 70.6% [48/68] after 2 months). The proportion of patients with anxiety and depressive symptoms (Hospital Anxiety and Depression Scale) decreased between baseline phase and third month of supplementation from 61.9% (39/63 patients with information available) to 35% (21/60) for depression and from 52.4% (33/63) to 30% (18/60) for anxiety. An improvement of quality of life (Qualité de Vie et Migraine questionnaire) was also observed. The combination was well tolerated.Results suggest that the proprietary supplement containing feverfew, coenzyme Q10 and magnesium assessed could be beneficial and safe for the prevention of migraine in adult patients and merits further study.ClinicalTrials.gov: NCT02901756 , retrospectively registered on August 24, 2016.

Dataset Information

Coenzyme Q10 supplementation for prophylaxis in adult patients with migraine-a meta-analysis.

Objective

Design

Data sources

Study selection

Data synthesis

Results

Conclusion

Prospero registration number

Publications

Coenzyme Q10 supplementation for prophylaxis in adult patients with migraine-a meta-analysis.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets